Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan First To Approve Omarigliptin, Lusutrombopag

This article was originally published in PharmAsia News

Executive Summary

The latest batch of product approvals in Japan includes the first regulatory clearances worldwide for new molecules from Merck and Shionogi, in a further sign that the country's "drug lag" is a thing of the past.

You may also be interested in...



14 Approvals To Look Out For In Q3

As many as 14 new products are up for US approval in the third quarter, research by Informa Pharma's Biomedtracker shows. Scrip takes a look at the candidates and their chances of reaching the market.

Dova’s Doptelet Gets First-To-Market Edge In Thrombocytopenia, Ahead Of Shionogi

Dova CEO Alex Sapir very confident of oral thrombopoietin receptor antagonist’s chances of taking market share from current standard of care, platelet transfusions, citing safety and convenience advantages.

New EU Submissions For Pfizer’s Lorlatinib, Teva’s Fremanezumab - And A CV Filing For Canakinumab

New products submitted for evaluation by the European Medicines Agency include Pfizer’s lorlatinib for lung cancer, Teva’s fremanezumab for migraine, and Shionogi’s lusutrombopag for thrombocytopenia. An already authorized drug, Novartis’s canakinumab, has been filed for a new use: reduction of cardiovascular risk.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC089203

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel